Semaglutide drug does not slow Alzheimer's progression

Semaglutide, the active ingredient in the weight loss drug Wegovy, has failed to slow the progression of Alzheimer's disease in clinical trials. Two large studies involving over 3,800 participants showed no difference in disease progression compared to a placebo. Researchers had investigated semaglutide due to initial hopes and real-world reports suggesting potential benefits. The results are a disappointment for Alzheimer's patients and highlight the complexity of the disease, emphasizing the need for multi-angled treatment approaches.